| scholarly article | Q13442814 |
| P50 | author | Simone Boehrer | Q117282086 |
| Guido Kroemer | Q19508945 | ||
| Lorenzo Galluzzi | Q28317088 | ||
| Pierre Fenaux | Q30170095 | ||
| Stéphane de Botton | Q57031523 | ||
| Lionel Adès | Q91775900 | ||
| P2093 | author name string | Antoine Martin | |
| Thorsten Braun | |||
| Claude Gardin | |||
| Claire Fabre | |||
| Jennifer Grosjean | |||
| Génèviève Le Roux | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erlotinib | Q418369 |
| P304 | page(s) | 2170-2180 | |
| P577 | publication date | 2007-10-09 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study | |
| P478 | volume | 111 |
| Q35093305 | A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia |
| Q37705923 | Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts |
| Q39439229 | Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia |
| Q39255686 | Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia |
| Q26827797 | Chloroquine and hydroxychloroquine for cancer therapy |
| Q43208673 | Dasatinib promotes ATRA-induced differentiation of AML cells |
| Q33409795 | Differentiation therapy of leukemia: 3 decades of development |
| Q36882696 | Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. |
| Q37420045 | EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells |
| Q38834981 | Emerging biological therapies for the treatment of myelodysplastic syndromes |
| Q39335663 | Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis |
| Q42383776 | Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia |
| Q36674536 | Epidermal growth factor regulates hematopoietic regeneration after radiation injury |
| Q36426524 | Erlotinib antagonizes ABC transporters in acute myeloid leukemia |
| Q42362038 | Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells |
| Q37406963 | Genomic approaches to small molecule discovery |
| Q39413114 | Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings |
| Q39623499 | Identification of new possible targets for leukemia treatment by kinase activity profiling |
| Q37680934 | Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens |
| Q36304190 | Independent transcriptional reprogramming and apoptosis induction by cisplatin |
| Q24297091 | Inhibition of autophagy by TAB2 and TAB3 |
| Q50514234 | Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice. |
| Q37815790 | Is there a role for differentiating therapy in non-APL AML? |
| Q37123272 | Lapatinib induces autophagic cell death and differentiation in acute myeloblastic leukemia |
| Q34117127 | Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells |
| Q51021428 | Non-small-cell lung cancer. |
| Q33414866 | Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. |
| Q41296140 | Prognostic value of LIPC in non-small cell lung carcinoma |
| Q34081881 | Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia |
| Q33577098 | Proteomic and genetic approaches identify Syk as an AML target |
| Q28548235 | Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells |
| Q37104233 | Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. |
| Q34628707 | Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome |
| Q24606978 | Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition |
| Q54524656 | SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. |
| Q26829903 | Signal transduction inhibitors in treatment of myelodysplastic syndromes |
| Q47928900 | Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome |
| Q34495409 | Survivin selectively modulates genes deregulated in human leukemia stem cells. |
| Q37694901 | Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist |
| Q34205052 | Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. |
| Q37981038 | The secret ally: immunostimulation by anticancer drugs |
| Q42702234 | Trial Watch: Adoptive cell transfer for anticancer immunotherapy |
| Q55260834 | Trial Watch: Chemotherapy with immunogenic cell death inducers. |
| Q36194849 | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy |
| Q36038408 | Trial Watch: Monoclonal antibodies in cancer therapy |
| Q28082910 | Trial Watch: Proteasomal inhibitors for anticancer therapy |
| Q33878578 | Trial Watch: Toll-like receptor agonists in oncological indications |
| Q26993238 | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy |
| Q27021951 | Trial Watch:: Oncolytic viruses for cancer therapy |
| Q28395830 | Trial watch: Cardiac glycosides and cancer therapy |
| Q55658029 | Trial watch: Chemotherapy with immunogenic cell death inducers. |
| Q42867339 | Trial watch: Dendritic cell-based interventions for cancer therapy |
| Q56932681 | Trial watch: Monoclonal antibodies in cancer therapy |
| Q42558833 | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications |
| Q89651597 | Turning liabilities into opportunities: Off-target based drug repurposing in cancer |
| Q33775647 | What are the endpoints of therapy for acute leukemias? Old definitions and new challenges |
Search more.